This study, called INTREPID, is looking at a drug called sapablursen for people with Polycythemia Vera (PV). PV is a blood disorder where your body makes too many red blood cells. The study wants to see how safe and effective sapablursen is when added to your usual PV treatment. You might be able to join if you are 18 or older, have been diagnosed with PV, and need regular blood draws (phlebotomy). Your red blood cell count (Hct) needs to be below 45% at the start of the study. The main goal is to see if sapablursen can help you avoid needing phlebotomy between weeks 20 and 32. The study is currently recruiting about 250 participants.

Study design

This is an interventional study with three parts, including a blinded treatment phase where you might receive sapablursen or a placebo (an inactive substance). You could receive treatment for up to 156 weeks.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures your need for phlebotomy between week 20 and week 32.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.